Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

Comparing Apixaban with Enoxaparin for Post-Surgical Extended-Duration VTEs Prophylaxis

admin by admin
November 23, 2022
in News


After abdominal or pelvic oncological surgery, a significant source of postoperative morbidity is venous thromboembolic events (VTEs). The use of enoxaparin, a subcutaneously injected low molecular weight heparin, for extended-duration VTE prophylaxis (EP) but has been linked to non-compliance. There is a lack of prospective research on the use of newer direct oral anticoagulants in the post-discharge scenario of urologic oncology. The primary objective of this research was to determine whether or if apixaban is equivalent to enoxaparin for EP, and the secondary goal was to increase EP adherence after abdominopelvic oncologic surgery. 

Between August 10, 2020 and September 21, 2021 to assess EP adherence and safety. For 6 months, researchers diligently tracked baseline stats, and then they switched from enoxaparin to apixaban across the board. Noninferiority sample size estimation was used to predict how long it would take to collect the necessary data (145 per group). Consequences of complying were the main measure of success (real or potential barriers to EP use). 

Complications within 30 days of discharge were a secondary result (symptomatic VTE or major bleed). By the end of the baseline period, 161 patients on enoxaparin and 154 on apixaban had been released from the hospital (intervention period). Patients who used enoxaparin were 3.1% more likely to experience an adverse event than those who took apixaban (0%). Predefined noninferiority criteria was satisfied with an absolute risk difference of 3.1% (95% CI: 0.043%-5.8%; P=0.028 for apixaban superiority). The percentage of patients experiencing compliance events while using enoxaparin was 33.5% (P=0.0001), while the percentage of patients taking apixaban was 14.3% (P=0.0001). 

When comparing enoxaparin and apixaban for EP following urologic oncology surgery, apixaban had fewer compliance events. Apixaban is equivalent to enoxaparin in terms of safety and may have less serious side effects.

Source: auajournals.org/doi/full/10.1097/JU.0000000000002788



Source link

Advertisement Banner
Previous Post

What Should Be in a First Responder’s Tactical Trauma Kit?

Next Post

Sleepwalking: Understanding Somnambulism – The Sleep Doctor

Related Posts

News

Insights from Normalization Process Theory

March 23, 2023
News

Transdermal Testosterone Pretreatment Improves Live Birth Rates in Poor Responders

March 22, 2023
News

Ph-positive Acute Lymphoblastic Leukaemia Treated with Ponatinib and Blinatumomab

March 21, 2023
News

High-Risk Hodgkin Lymphoma and BV+Nivolumab After HSCT

March 20, 2023
News

History of Adverse Pregnancy Outcomes Linked to Coronary Artery Disease

March 19, 2023
News

American College of Cardiology, March 4 to 6

March 18, 2023
Next Post

Sleepwalking: Understanding Somnambulism - The Sleep Doctor

Recommended

Pacemaker Apps Cartoon

2 weeks ago

Community health center malpractice cases leave taxpayers to pay up

4 months ago

9 states that prefiled anti-trans bills ahead of legislative session

3 months ago

Playwright puts racism in health care on the stage

2 months ago

IBD Outcomes Improved With Financial Assistance Program

3 months ago

© 2022 Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.